[Home]  [Headlines]  [Latest Articles]  [Latest Comments]  [Post]  [Mail]  [Sign-in]  [Setup]  [Help]  [Register] 

"Analysis: The Final State of the Presidential Race"

He’ll, You Pieces of Garbage

The Future of Warfare -- No more martyrdom!

"Kamala’s Inane Talking Points"

"The Harris Campaign Is Testament to the Toxicity of Woke Politics"

Easy Drywall Patch

Israel Preparing NEW Iran Strike? Iran Vows “Unimaginable” Response | Watchman Newscast

In Logansport, Indiana, Kids are Being Pushed Out of Schools After Migrants Swelled County’s Population by 30%: "Everybody else is falling behind"

Exclusive — Bernie Moreno: We Spend $110,000 Per Illegal Migrant Per Year, More than Twice What ‘the Average American Makes’

Florida County: 41 of 45 People Arrested for Looting after Hurricanes Helene and Milton are Noncitizens

Presidential race: Is a Split Ticket the only Answer?

hurricanes and heat waves are Worse

'Backbone of Iran's missile industry' destroyed by IAF strikes on Islamic Republic

Joe Rogan Experience #2219 - Donald Trump

IDF raids Hezbollah Radwan Forces underground bases, discovers massive cache of weapons

Gallant: ‘After we strike in Iran,’ the world will understand all of our training

The Atlantic Hit Piece On Trump Is A Psy-Op To Justify Post-Election Violence If Harris Loses

Six Al Jazeera journalists are Hamas, PIJ terrorists

Judge Aileen Cannon, who tossed Trump's classified docs case, on list of proposed candidates for attorney general

Iran's Assassination Program in Europe: Europe Goes Back to Sleep

Susan Olsen says Brady Bunch revival was cancelled because she’s MAGA.

Foreign Invaders crisis cost $150B in 2023, forcing some areas to cut police and fire services: report

Israel kills head of Hezbollah Intelligence.

Tenn. AG reveals ICE released thousands of ‘murderers and rapists’ from detention centers into US streets

Kamala Harris Touts Mass Amnesty Offering Fast-Tracked Citizenship to Nearly Every Illegal Alien in U.S.

Migration Crisis Fueled Rise in Tuberculosis Cases Study Finds

"They’re Going to Try to Kill Trump Again"

"Dems' Attempts at Power Grab Losing Their Grip"

"Restoring a ‘Great Moderation’ in Fiscal Policy"

"As attacks intensify, Trump becomes more popular"

Posting Articles Now Working Here

Another Test

Testing

Kamala Harris, reparations, and guaranteed income

Did Mudboy Slim finally kill this place?

"Why Young Americans Are Not Taught about Evil"

"New Rules For Radicals — How To Reinvent Kamala Harris"

"Harris’ problem: She’s a complete phony"

Hurricane Beryl strikes Bay City (TX)

Who Is ‘Destroying Democracy In Darkness?’

‘Kamalanomics’ is just ‘Bidenomics’ but dumber

Even The Washington Post Says Kamala's 'Price Control' Plan is 'Communist'

Arthur Ray Hines, "Sneakypete", has passed away.

No righT ... for me To hear --- whaT you say !

"Walz’s Fellow Guardsmen Set the Record Straight on Veep Candidate’s Military Career: ‘He Bailed Out’ "

"Kamala Harris Selects Progressive Minnesota Governor Tim Walz as Running Mate"

"The Teleprompter Campaign"

Good Riddance to Ismail Haniyeh

"Pagans in Paris"

"Liberal groupthink makes American life creepy and could cost Democrats the election".


Status: Not Logged In; Sign In

U.S. Constitution
See other U.S. Constitution Articles

Title: Dopers Meet Reality - U.S. v. Walsh. 6th Cir. (29 Jun 2016
Source: U.S. Ct. App., 6th Circuit
URL Source: [None]
Published: Jun 29, 2016
Author: JANE B. STRANCH, Circuit Judge
Post Date: 2016-08-25 14:19:08 by nolu chan
Keywords: None
Views: 2262
Comments: 13

Dopers Meet Reality - U.S. v. Walsh. 6th Cir. (29 Jun 2016)

http://cases.justia.com/federal/appellate-courts/ca6/15-1569/15-1569-2016-06-29.pdf?ts=1467216038

UNITED STATES COURT OF APPEALS FOR THE SIXTH CIRCUIT

No. 15-1569 (6th Cir. Jun 29, 2016)

United States v. Walsh

JANE B. STRANCH, Circuit Judge.

NOT RECOMMENDED FOR PUBLICATION

ON APPEAL FROM THE UNITED STATES DISTRICT COURT FOR THE WESTERN DISTRICT OF MICHIGAN OPINION BEFORE: KEITH, COOK, and STRANCH, Circuit Judges.

JANE B. STRANCH, Circuit Judge.

Phillip Joseph Walsh and Betty Lee Jenkins appeal the final judgments against them on one count of conspiracy to manufacture 100 or more marijuana plants and eleven counts of maintaining drug-involved premises. They raise several common claims on appeal, largely based on the district court's in-limine order precluding the defendants from introducing evidence regarding their compliance with Michigan's Medical Marihuana Act (MMMA). Jenkins also separately challenges the district court's denial of her motions to suppress statements and evidence collected during the search of her properties and challenges the reasonableness of her sentence. For the reasons set forth below, we AFFIRM the orders of the district court.

Walsh and Jenkins were charged as co-conspirators (along with several others) and tried as co-defendants. On appeal, their cases were consolidated for the purposes of briefing and submission.

[...]

A. Claims Related to the District Court's In-Limine Order

Walsh and Jenkins contend that the district court's order precluding them from arguing or introducing evidence related to their compliance with Michigan medical marijuana laws violated their due process right to present a defense. In light of Section 538 of the 2015 Appropriations Act, they contend that compliance with state law provides immunity and an affirmative defense against federal marijuana charges. In evaluating the charges against them, Walsh and Jenkins assert that the jury should have considered whether their manufacture of marijuana conformed to the MMMA. They further contend that the Government failed to comply with the district court's in-limine order to such an extent that it constituted prosecutorial misconduct.

The Government responds that Walsh and Jenkins have waived these arguments, as they made no objection during trial and the arguments are raised for the first time on appeal. Even if they were not waived, the Government maintains, these claims afford no relief.

1. Evidence Relating to Michigan's Medical Marihuana Act

A motion in limine is "made before or during trial, to exclude anticipated prejudicial evidence before the evidence is actually offered." Luce v. United States, 469 U.S. 38, 40 n.2 (1984). It is "designed to narrow the evidentiary issues for trial and to eliminate unnecessary trial interruptions." Louzon v. Ford Motor Co., 718 F.3d 556, 561 (6th Cir. 2013) (quoting Bradley v. Pittsburgh Bd. of Educ., 913 F.2d 1064, 1069 (3d Cir. 1990)).

The district court granted several of the Government's motions in limine, including motions to prevent Walsh and Jenkins from arguing or introducing evidence to suggest (1) marijuana has medical value, (2) their erroneous belief that their conduct was lawful, or (3) compliance with state law. As for the last, the Government cited People v. Redden, 799 N.W.2d 184 (Mich. Ct. App. 2010) (P.J. O'Connell, concurring), for the proposition that Michigan courts have "cautioned citizens and legal counsel not to rely upon the MMMA even for protection against criminal charges arising under state law." That concurring opinion advised that "[u]ntil our Supreme Court provides a final comprehensive interpretation of [the MMMA], it would be prudent for the citizens of this state to avoid all use of marijuana if they do not wish to risk violating state law." Redden, 799 N.W.2d at 204 n.10.

In considering these motions, the district court noted that while conspiracy is a specific intent crime, conspirators must only have the "specific, willful intent to enter into the agreement with others and achieve the objective of the conspiracy," in this case, growing marijuana. The Government need not show that Walsh and Jenkins "intended to willfully violate federal drug laws or knew that their actions violated the Controlled Substances Act." The district court determined that a good faith belief in the legality of the operation was therefore irrelevant and, while this ruling hindered the ability of the defense to paint a complete picture, "irrelevant evidence is never admissible." Concluding that "the only reason to discuss compliance with Michigan's medical marijuana laws [was] to encourage jury nullification or establish a defense that [was] not valid," the court granted the Government's motion on this subject.

[...]

b. Analysis

Marijuana is designated as a Schedule I drug by the federal Controlled Substances Act (CSA) due to its "high potential for abuse, lack of any accepted medical use, and absence of any accepted safety for use in medically supervised treatment." Gonzales v. Raich, 545 U.S. 1, 14 (2005) (citing 21 U.S.C. §§ 812(b)(1) & (c)). By the terms of the Act, marijuana is "contraband for any purpose," and, "if there is any conflict between federal and state law" with regard to marijuana legislation, "federal law shall prevail" pursuant to the Supremacy Clause. Id. at 27, 29.

The Supreme Court has further clarified that there is no medical necessity exception to the CSA prohibition on cultivation and distribution of marijuana. See United States v. Oakland Cannabis Buyers' Coop., 532 U.S. 483, 486 (2001). "Although state law may permit marijuana use for medicinal purposes under defined circumstances, federal law treats any possession, distribution, or manufacture of marijuana as a federal offense, and medical necessity is not a defense to a federal criminal prosecution for manufacturing or distributing marijuana." United States v. Brown, 801 F.3d 679, 693 (6th Cir. 2015) (citing Oakland Cannabis Buyers' Coop., 532 U.S. at 493-94). In Gonzalez v. Raich, the Supreme Court held that the CSA's prohibition of the manufacture and distribution of marijuana was a valid exercise of congressional power pursuant to the Commerce Clause. 545 U.S. at 29. The commerce power is "superior to that of the States to provide for the welfare or necessities of their inhabitants, however legitimate or dire those necessities may be." Id. (internal quotation marks omitted).

This precedent proved fatal as applied to a case similar to the one now before us, where defendants challenged their federal conviction for manufacturing more than 100 marijuana plants on the basis that the CSA was "unconstitutional as applied to caregivers operating in compliance with the MMMA." United States v. Marcinkewciz, 543 F. App'x 513, 516 (6th Cir. 2013). There, we determined that defendants had offered no way to distinguish their arguments from those rejected by the Supreme Court, and we held them foreclosed by Raich. Id.

Walsh and Jenkins contend that Section 538 of the 2015 Appropriations Act changed the legal landscape in which Raich was decided. In support, Walsh cites United States v. Marin Alliance for Medical Marijuana, a civil case from the Northern District of California that interpreted Section 538 to preclude enforcement of a permanent injunction prohibiting distribution of medical marijuana by a dispensary to the extent that it complied with California law. No. C 98-00086 CRB, 2015 WL 6123062, at *6 (N.D. Cal. Oct. 19, 2015).

Section 538 states in relevant part:

None of the funds made available in this Act to the Department of Justice may be used, with respect to the [states with medical marijuana laws, including California and Michigan] to prevent such States from implementing their own State laws that authorize the use, distribution, possession, or cultivation of medical marijuana.

Consolidated and Further Continuing Appropriations Act, 2015, Pub. L. No. 113-235, § 538, 128 Stat. 2130 (2014) (extended until Dec. 11, 2015, by the 2016 Appropriations Act, Pub. L. No. 114-53, § 103, 129 Stat. 502 (2015)). After considering this plain language, and the relevant legislative history, the Marin Alliance court interpreted Section 538 to provide an exception to the rule that state law offers no defense to violations of federal marijuana law. The court acknowledged that "[t]he CSA remains in place" and committed to "enforce it to the full extent that Congress has allowed in Section 538, that is, with regard to any medical marijuana not in full compliance with 'State law [ ] that authorize[s] the use, distribution, possession, or cultivation of medical marijuana.'" Marin All., 2015 WL 6123062, at *4 (citing 2015 Appropriations Act § 538) (alterations in original).

Walsh and Jenkins argue that Section 538 changed the legal environment surrounding medical marijuana, by "prohibit[ing] the Government from prosecuting individuals who are acting in accordance with their state's medical marijuana laws." Therefore, they conclude, the district court "violated Defendant's due process right to present a defense" by granting the relevant motion in limine, and by failing to "reconsider its decision in light of the enactment of Section 538," which deprived them of the opportunity to establish immunity or an affirmative defense under the MMMA.

To demonstrate immunity, which Walsh contends is a question of law, "a defendant must prove by a preponderance of the evidence that at the time of the charged offense the defendant possessed a valid registry card, no more medicine than allowed under section 4, that the plants were kept locked in an enclosed facility, and that the charged conduct was for medical use." (Walsh Appellant Br. at 23) (citing People v. Hartwick, 870 N.W.2d 37, 42 (Mich. 2015)).

For cases that fall outside of the immunity parameters, Walsh argues that Section 8 of the MMMA can provide an affirmative defense if a defendant establishes the existence of a bona fide physician-patient relationship, that the amount of marijuana was an amount reasonably necessary to prevent an interrupted supply, and that the alleged conduct was for medical use. (Walsh Appellant Br. at 24) (citing Mich. Comp. L. § 333.26428). He contends this is a question of fact. Id. (citing Hartwick, 870 N.W. at 56).

We cannot conclude that the district court abused its discretion by precluding evidence of compliance with Michigan medical marijuana laws. Though the legal treatment of marijuana, both medical and recreational, has continued to change in the ten years since Gonzalez was decided, it remains good law. The district court granted the motions in limine on the basis that the manufacture and distribution of Schedule I drugs, including marijuana, is prohibited under the terms of the CSA. The district court explained that satisfaction of state law is not a defense to breaching federal law; thus, compliance with Michigan law is irrelevant when considering a defendant's guilt or innocence under federal law.

Section 538 did not render this legal standard incorrect. While, by its terms, Section 538 instructs the Department of Justice on where to spend its funds with respect to marijuana cultivation and distribution, it was not an abuse of discretion to determine that Section 538 did not require the court to halt or alter this criminal prosecution in its final stages. The district court's failure to reconsider its order regarding the Government's motions in limine on the basis of Section 538, when the 2015 Appropriations Act came into effect just weeks before the trial and no party raised the matter at trial, is not a clear error of judgment. See Louzon, 718 F.3d at 560.

[snip]

Post Comment   Private Reply   Ignore Thread  


TopPage UpFull ThreadPage DownBottom/Latest

Begin Trace Mode for Comment # 11.

#11. To: nolu chan (#0)

Just for the record, and for the 498th time-

THE FEDERAL GOVERNMENT HOLDS A PATENT ON THE MAIN INGREDIENT IN CANNABIS

AND HAS SINCE 2003. THIS SAME GOVERNMENT THAT SAYS THERE IS NO MEDICAL USE FOR THIS PLANT.

US PATENT #6630507

United States Patent 6,630,507 Hampson , et al. October 7, 2003 Assignee: The United States of America as represented by the Department of Health and Human Services (Washington, DC) Cannabinoids as antioxidants and neuroprotectants

Abstract Cannabinoids have been found to have antioxidant properties, unrelated to NMDA receptor antagonism. This new found property makes cannabinoids useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases. The cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease and HIV dementia.

http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6630507.PN.&OS=PN/6630507&RS=PN/6630507

And 29 or so other patents have either been applied for or granted:

US Patent 4189491 – Tetrahydrocannabinol (THC) in a method of treating glaucoma (1980)

US Patent 4315862 – Process for preparing cannabichromene (1982)

US Patent 5389375 – Stable suppository formulations effecting bioavailability of ”9-THC (1995)

US Patent 5508037 – Stable suppository formulations effecting bioavailability of ”9 -THC (1996)

US Patent 6132762 – Transcutaneous application of marijuana (2000)

US Patent 6328992 – Cannabinoid patch and method for cannabis transdermal delivery (2001)

US Patent 6383513 – Compositions comprising cannabinoids (nasal spray) (2002)

US Patent Application 20050042172 – Administration of medicaments by vaporisation (2002)

US Patent Application 20070151149 – Methods for altering the level of phytochemicals in plant cells by applying wave lengths of light from 400 nm to 700 nm and apparatus therefore (2004)

US Patent Application 20040049059 A1 – Method for producing an extract from cannabis plant matter, containing a tetrahydrocannabinol and a cannabidiol and cannabis extracts (2004)

US Patent 6713048 – ”9 tetrahydrocannabinol (”9 THC) solution metered dose inhalers and methods of use (2004)

US Patent 6974568 – The invention discloses the existence of cannabinoid receptors in the airways, which are functionally linked to inhibition of cough (2005)

US Patent Application 20050266108 – Methods of purifying cannabinoids from plant material (2005)

US Patent 6949582 – Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment (2005)

Grow Hemp for the War

US Patent Application 20050070596 – Methods for treatment of inflammatory diseases using CT-3 or analogs thereof (2005)

US Patent 6949582 – Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment (2005)

US Patent 7088914 – Device, method and resistive element for vaporizing a medicament (2006)

US Patent 7025992 – Administering lipophilic drug through mucous membranes(2006)

US Patent Application 20060242899 – Method of cultivating plants (2006)

US Patent 7109245 – Vasoconstrictor cannabinoid analogs (2006)

US Patent Application 20080057117 – Pharmaceutical Composition Made Up Of Cannabis Extracts (2007)

US Patent 7344736 – Extraction of pharmaceutically active components from plant materials (2008)

US Patent 7402686 – Cannabinoid crystalline derivatives and process of cannabinoid purification (2008)

US Patent 7399872 – Conversion of CBD to ”-THC and ”-THC (2008)

US Patent 7622140 – Processes and apparatus for extraction of active substances and enriched extracts from natural products (2009)

US Patent application 20100249223 New Use for Cannabis Containing Extracts (2010)

US Patent application 20100239693 Cannabinoid Containing Plant Extracts As Neuroprotective Agents (2010)

Cancer.gov: Cannabis and Cannabinoids (PDQ®)–Patient Version

The use of Cannabis for medicinal purposes dates back to ancient times

Cannabis has been shown to kill cancer cells in the laboratory

MORE: http://www.cancer.gov/about-cancer/treatment/cam/patient/cannabis-pdq

Operation 40  posted on  2016-08-28   17:39:27 ET  Reply   Untrace   Trace   Private Reply  


Replies to Comment # 11.

#12. To: All, Senior Blanco, Deniers (#11)

Bump for Drug Warriors- where are you. Denial is not just a river in Egypt.

Operation 40  posted on  2016-08-28 22:01:06 ET  Reply   Untrace   Trace   Private Reply  


#13. To: Operation 40, misterwhite (#11)

THE FEDERAL GOVERNMENT HOLDS A PATENT ON THE MAIN INGREDIENT IN CANNABIS

AND HAS SINCE 2003. THIS SAME GOVERNMENT THAT SAYS THERE IS NO MEDICAL USE FOR THIS PLANT.

Cannabidioils are legal and can be extracted from hemp.

The exicting news is "The United States Drug Enforcement Administration, the DEA, recently eased some of the regulatory requirements for those who are conducting FDA-approved clinical trials on cannabidiol (CBD)." Clinical trials to provide the medicine so many desire are being performed.

http://www.google.ca/patents/US6630507

THE PATENT

Cannabinoids as antioxidants and neuroprotectants

US 6630507 B1

Abstract

Cannabinoids have been found to have antioxidant properties, unrelated to NMDA receptor antagonism. This new found property makes cannabinoids useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases. The cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease and HIV dementia. Nonpsychoactive cannabinoids, such as cannabidoil, are particularly advantageous to use because they avoid toxicity that is encountered with psychoactive cannabinoids at high doses useful in the method of the present invention.

[...]

Cannabidiol is not on the list of psychotropic substances. It is a legal. Unfortunately for dopers, it is "substantially free of psychoactive or psychotoxic effects" (it won't get you high). It can be extracted from hemp.

https://en.wikipedia.org/wiki/Cannabidiol

Legal status

Cannabidiol is not scheduled by the Convention on Psychotropic Substances. CBD does not cause the "high" associated with the Delta 9-THC in marijuana. As the legal landscape and understanding about the differences in medical cannabinoids unfolds, it will be increasingly important to distinguish “medical marijuana” (with noted varying degrees of psychotropic effects and deficits in executive function) - from “medical CBD” (in which the high CBD and low THC content may mitigate psychosis).

Various breeds/strains of "medical marijuana" are found to have a significant variety in the ratios of CBD-to-THC and are known to contain other non-psychotropic cannabinoids. However it is only the amount of Delta 9-THC that chemically gives a legal determination as to whether the plant material(s) used for the purposes of extracting CBD are considered hemp, or considered marijuana.

Any psychoactive marijuana, regardless of its CBD content, is derived from the flower (or bud) of the genus cannabis. Non-psychoactive hemp (also commonly-termed industrial hemp), regardless of its CBD content, is any part of the genus cannabis plant, whether growing or not, containing a Delta-9 tetrahydrocannabinol concentration of no more than three-tenths of one percent (0.3%) on a dry weight basis. Certain standards are required for the legal growth and production of hemp. The Colorado Industrial Hemp Program registers growers of industrial hemp and samples crops to verify that the THC concentration does not exceed 0.3% on dry weight basis.

With Charlotte's Web bringing about increased demand for CBD-dominant cannabis, cultivating hemp has captured the attention of U.S. farmers looking to replace dwindling tobacco-growing revenues with renewed hemp "cash crops." In Kentucky, farmers are spurred on by the Industrial Hemp Research Program, established by James Comer, commissioner of agriculture. With backing from Senator Rand Paul, Comer’s legislation created regulations for farmers to legally grow hemp.

Joel Stanley, CEO of Stanley Brothers Social Enterprises, said they plan to invest at least $500,000 to grow therapeutic hemp in Kentucky for their Charlotte's Web cannabidiol oil, saying, "We want to make Charlotte's Web a Kentucky Proud product." In addition, Paul and Comer were able to get a provision added to the federal Farm Bill that legalized hemp production in states like Kentucky to grow the crop. The Agricultural Act of 2014 was signed by President Obama.

During recent years, there has been considerable legislative activity throughout the United States with respect to legalizing the agricultural production of industrial hemp. To date, approximately 11 states have legalized industrial hemp production, including: California, Colorado, Indiana, Maine, Montana, North Dakota, Oregon, South Carolina, Vermont, West Virginia, and Tennessee. Many other states have passed legislation authorizing the cultivation of industrial hemp for pilot projects or studies, including: Connecticut, Delaware, Hawaii, Illinois, Kentucky, Nebraska, and Utah. Additionally, the National Association of State Departments of Agriculture and the National Conference of State Legislatures have both adopted resolutions supporting revisions to the federal rules and regulations authorizing commercial production of industrial hemp.

The United States Drug Enforcement Administration, the DEA, recently eased some of the regulatory requirements for those who are conducting FDA-approved clinical trials on cannabidiol (CBD).

Several industrial hemp varieties can be legally cultivated in western Europe. A variety such as "Fedora 17" has a cannabinoid profile consistently around 1% cannabidiol (CBD) with THC less than 0.1%.

nolu chan  posted on  2016-08-29 02:22:19 ET  Reply   Untrace   Trace   Private Reply  


End Trace Mode for Comment # 11.

TopPage UpFull ThreadPage DownBottom/Latest

[Home]  [Headlines]  [Latest Articles]  [Latest Comments]  [Post]  [Mail]  [Sign-in]  [Setup]  [Help]  [Register] 

Please report web page problems, questions and comments to webmaster@libertysflame.com